{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:02:07Z","timestamp":1787022127585,"version":"build-2736575974"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MSD Sweden"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Pneumococcal disease is a major cause of clinical and economic burden worldwide. This study investigated the burden of pneumococcal disease in Swedish adults. A retrospective population-based study was conducted using Swedish national registers, including all adults aged \u226518 years with a diagnosis of pneumococcal disease (defined as pneumococcal pneumonia, meningitis, or septicemia) in inpatient or outpatient specialist care between 2015\u20132019. Incidence and 30-day case fatality rates, healthcare resource utilization, and costs were estimated. Results were stratified by age (18\u201364, 65\u201374, and \u226575 years) and the presence of medical risk factors. A total of 10,391 infections among 9,619 adults were identified. Medical factors associated with higher risk for pneumococcal disease were present in 53% of patients. These factors were associated with increased pneumococcal disease incidence in the youngest cohort. In the cohort aged 65\u201374 years, having a very high risk for pneumococcal disease was not associated with an increased incidence. Pneumococcal disease incidence was estimated at 12.3 (18\u201364), 52.1 (64\u201374), and 85.3 (\u226575) per 100,000 population. The 30-day case fatality rate increased with age (18\u201364: 2.2%, 65\u201374: 5.4%, \u226575: 11.7%), and was highest among septicemia patients aged \u226575 (21.4%). The 30-day average number of hospitalizations was 1.13 (18\u201364), 1.24 (64\u201374) and 1.31 (\u226575). The average 30-day cost\/infection was estimated at \u20ac4,467 (18\u201364), \u20ac5,278 (65\u201374), and \u20ac5,898 (\u226575). The 30-day total direct cost of pneumococcal disease between 2015\u20132019 was \u20ac54.2 million, with 95% of costs from hospitalizations. The clinical and economic burden of pneumococcal disease in adults was found to increase with age, with nearly all costs associated with pneumococcal disease from hospitalizations. The 30-day case fatality rate was highest in the oldest age group, though not negligible in the younger age groups. The findings of this study can inform the prioritization of pneumococcal disease prevention in adult and elderly populations.<\/jats:p>","DOI":"10.1371\/journal.pone.0287581","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T13:27:04Z","timestamp":1688736424000},"page":"e0287581","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical and economic burden of pneumococcal disease among adults in Sweden: A population-based register study"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1004-320X","authenticated-orcid":true,"given":"Natalie","family":"Zarabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Aldv\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Sj\u00f6lander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Fues Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6293-8211","authenticated-orcid":true,"given":"Goran","family":"Bencina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly D.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3606-3797","authenticated-orcid":true,"given":"Sven-Arne","family":"Silfverdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"issue":"6","key":"pone.0287581.ref001","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/1403494815581695","article-title":"Clinical burden of pneumonia, meningitis and septicemia in Norway 2 years after 7-valent pneumococcal conjugate vaccine introduction","volume":"43","author":"S Munson","year":"2015","journal-title":"Scand J Public Health"},{"issue":"8","key":"pone.0287581.ref002","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1080\/21645515.2016.1159363","article-title":"Surveillance of pneumococcal diseases in Central and Eastern Europe.","volume":"12","author":"M Ceyhan","year":"2016","journal-title":"Human vaccines & immunotherapeutics."},{"issue":"Suppl 5","key":"pone.0287581.ref003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/1469-0691.12461","article-title":"Pneumococcal infection in adults: burden of disease","volume":"20","author":"JJ Drijkoningen","year":"2014","journal-title":"Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"issue":"6","key":"pone.0287581.ref004","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/joim.12956","article-title":"The changing epidemiology of community-acquired pneumonia: nationwide register-based study in Sweden","volume":"286","author":"P Naucler","year":"2019","journal-title":"J Intern Med"},{"issue":"5","key":"pone.0287581.ref005","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40266-013-0060-5","article-title":"Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.","volume":"30","author":"A Vila-Corcoles","year":"2013","journal-title":"Drugs Aging"},{"issue":"11","key":"pone.0287581.ref006","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/cid\/cix685","article-title":"Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations","volume":"65","author":"P Naucler","year":"2017","journal-title":"Clin Infect Dis"},{"key":"pone.0287581.ref007","article-title":"The Public Health Agency of Sweden","year":"2020","journal-title":"Pneumokockinfektion\u2014invasiv (Pneumococcal infection\u2014invasive)"},{"key":"pone.0287581.ref008","article-title":"The Public Health Agency of Sweden","year":"2016","journal-title":"Pneumokockvaccination till riskgrupper\u2014ett kunskapsunderlag (Pneumococcal vaccination for risk groups\u2014knowledge basis)."},{"issue":"3","key":"pone.0287581.ref009","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/14760584.2021.1880328","article-title":"Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence","volume":"20","author":"MS Niederman","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"pone.0287581.ref010","article-title":"The Public Health Agency of Sweden.","year":"2020","journal-title":"Rekommendationer om pneumokockvaccination till riskgrupper (Recommendations on pneumococcal vaccination for risk groups)."},{"key":"pone.0287581.ref011","unstructured":"Stora satsningar p\u00e5 v\u00e4lf\u00e4rden och \u00e4ldreomsorgen (Major investments in social welfare and elderly care) [Internet]. https:\/\/www.regeringen.se\/pressmeddelanden\/2021\/09\/stora-satsningar-pa-valfarden-och-aldreomsorgen\/; 2021 [cited 2021-10-21]. Available from: https:\/\/www.regeringen.se\/pressmeddelanden\/2021\/09\/stora-satsningar-pa-valfarden-och-aldreomsorgen\/"},{"key":"pone.0287581.ref012","article-title":"1177 V\u00e5rdguiden","year":"2021","journal-title":"Vaccination mot pneumokocker (Vaccination for pneumococci)"},{"key":"pone.0287581.ref013","doi-asserted-by":"crossref","first-page":"17562848211023386","DOI":"10.1177\/17562848211023386","article-title":"Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study.","volume":"14","author":"C Eriksson","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"pone.0287581.ref014","article-title":"S\u00f6dra Regionv\u00e5rdsn\u00e4mnden","year":"2021","journal-title":"Regionala priser och ers\u00e4ttningar f\u00f6r s\u00f6dra sjukv\u00e5rdsregionen (Regional prices and compensation for the southern healthcare region)."},{"key":"pone.0287581.ref015","author":"Sveriges Riksbank","year":"2021","journal-title":"Annual average exchange rates (aggregate)\u2014SEK\u2014EUR"},{"issue":"4","key":"pone.0287581.ref016","first-page":"e60273","article-title":"Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques.","volume":"8","author":"Team AAPBS","year":"2013","journal-title":"PLoS One.PubMed Central PMCID"},{"issue":"2","key":"pone.0287581.ref017","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1086\/648678","article-title":"Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods","volume":"50","author":"N Johansson","year":"2010","journal-title":"Clin Infect Dis"},{"key":"pone.0287581.ref018","article-title":"Centers for Disease Control and Prevention","year":"2021","journal-title":"Pinkbook\u2014Epidemiology and Prevention of Vaccine-Preventable Diseases\u2014Chapter 17: Pneumococcal Disease"},{"key":"pone.0287581.ref019","article-title":"Kvalitetsregistret infektion","year":"2019","journal-title":"Rapport fr\u00e5n Pneumoniregistret 2019 (Report from the registry of pneumonia 2019)."},{"issue":"6","key":"pone.0287581.ref020","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/thoraxjnl-2012-203106","article-title":"Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia.","volume":"68","author":"P Naucler","year":"2013","journal-title":"Thorax"},{"key":"pone.0287581.ref021","article-title":"Swedish National Board of Health and Welfare","journal-title":"Socialstyrelsens statistikdatabas: Diagnoser, Endast sluten v\u00e5rd, Medelv\u00e5rdtid, Samtliga v\u00e5rdtillf\u00e4llen, Riket (Statistical database) 2015\u20132019"},{"key":"pone.0287581.ref022","first-page":"2303","article-title":"Health care and social care costs of pneumonia in Denmark: a register-based study of all citizens and patients with COPD in three municipalities.","volume":"10","author":"SL Brogaard","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"8","key":"pone.0287581.ref023","doi-asserted-by":"crossref","first-page":"e42595","DOI":"10.1371\/journal.pone.0042595","article-title":"Invasive pneumococcal disease in healthy adults: increase of empyema associated with the clonal-type Sweden(1)-ST306.","volume":"7","author":"I Grau","year":"2012","journal-title":"PLoS One.PubMed Central PMCID"},{"issue":"1","key":"pone.0287581.ref024","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jinf.2012.02.017","article-title":"The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England.","volume":"65","author":"AJ van Hoek","year":"2012","journal-title":"J Infect"},{"key":"pone.0287581.ref025","article-title":"Risk factors and pathogen characteristics associated with unfavorable outcomes among adults with pneumococcal meningitis in Japan, 2006 to 2016.","author":"S Iwata","year":"2023","journal-title":"J Infect Chemother."},{"key":"pone.0287581.ref026","year":"2020","journal-title":"Statens serum institut. Pneumococcal vaccination programme for persons aged 65 years or more and for risk groups"},{"key":"pone.0287581.ref027","article-title":"The Public Health Agency of Sweden","year":"2016","journal-title":"Pneumokockvaccination som s\u00e4rskilt vaccinationsprogram\u2014H\u00e4lsoekonomisk utv\u00e4rdering (Pneumococcal vaccination as a special vaccination program\u2014Health economic evaluation)."},{"issue":"32","key":"pone.0287581.ref028","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.vaccine.2020.05.072","article-title":"Cost-effectiveness of pneumococcal vaccination for elderly in Sweden","volume":"38","author":"E Wolff","year":"2020","journal-title":"Vaccine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0287581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T13:27:27Z","timestamp":1688736447000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0287581"}},"subtitle":[],"editor":[{"given":"Tushar","family":"Shaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0287581","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}